Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial.

Authors

Aditya H Gaur
Hilda Kizito
Wasana Prasitsueubsai
Natella Rakhmanina, George Washington University
Mohammed Rassool
Rana Chakraborty
Jagmohan Batra
Pope Kosalaraksa
Wicharn Luesomboon
Danielle Porter
Yongwu Shao
Michael Myers
Lillian Ting
Devi SenGupta
Erin Quirk
Martin S Rhee

Document Type

Journal Article

Publication Date

10-17-2016

Journal

Lancet HIV

DOI

10.1016/S2352-3018(16)30121-7

APA Citation

Gaur, A., Kizito, H., Prasitsueubsai, W., Rakhmanina, N., Rassool, M., Chakraborty, R., Batra, J., Kosalaraksa, P., Luesomboon, W., Porter, D., Shao, Y., Myers, M., Ting, L., SenGupta, D., Quirk, E., & Rhee, M. (2016). Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial.. Lancet HIV, (). http://dx.doi.org/10.1016/S2352-3018(16)30121-7

Peer Reviewed

1